Titlebook: Bone Drugs in Pediatrics; Efficacy and Challen Gordon L. Klein Book 2014 Springer Science+Business Media New York 2014 Anti-resorptive.Bisp

Holter-monitor

書目名稱Bone Drugs in Pediatrics影響因子(影響力)




書目名稱Bone Drugs in Pediatrics影響因子(影響力)學科排名




書目名稱Bone Drugs in Pediatrics網(wǎng)絡公開度




書目名稱Bone Drugs in Pediatrics網(wǎng)絡公開度學科排名




書目名稱Bone Drugs in Pediatrics被引頻次




書目名稱Bone Drugs in Pediatrics被引頻次學科排名




書目名稱Bone Drugs in Pediatrics年度引用




書目名稱Bone Drugs in Pediatrics年度引用學科排名




書目名稱Bone Drugs in Pediatrics讀者反饋




書目名稱Bone Drugs in Pediatrics讀者反饋學科排名

懦夫

Drug Development for Pediatric Diseases with Bone Loss,. We will provide the rationale for developing new anabolic drugs for treatment of bone loss in children. Three different approaches for drug discovery will be described, and new development of bone biology related to drug discovery target will be discussed in detail. Finally, we will talk about dru

人類

樹木心

ing these drugs in the pediatric population.Highlights the p.Bone Drugs in Pediatrics. brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their

indifferent

https://doi.org/10.1007/978-3-662-12301-0thyroid hormone-related peptide, and their analogs. We also consider new molecules that are currently under development or of interest, including cathepsin K inhibitors, antisclerostin antibody, and nitric oxide.

FANG

urethritis

引起

Vo2-Max

Growth Hormone and Bone,. To improve linear growth and bone mineral metabolism, some recent studies have challenged GH treatment in patients with metabolic bone diseases, in addition to approved diseases. In this chapter, we describe the physiology of GH action, efficacy, and trials of GH treatment. The especially on bone mineral metabolism.

breadth

Growth Hormone and Oxandrolone in Burned Children,g post-burn bone health outcomes. The systemic action of these anabolic agents beyond the bone metabolic system has also been explored in the clinical trials described. However, only bone-related markers are discussed in detail in this chapter.